You can now read 10 articles a month for free. Read as much as you want anywhere and anytime for just 99¢.

mass. movers

Agenus slumps as clinical tests disappoint

Glaxo is studying drugs that use a compound from Lexington-based Agenus.

Associated Press/File 2010

Glaxo is studying drugs that use a compound from Lexington-based Agenus.

Continue reading below

Agenus Inc. fell sharply after an unsuccessful clinical trial of a cancer treatment that includes its compound that is designed to make drugs more effective. British drug maker GlaxoSmithKline is studying cancer treatments that include Agenus’s SQ-21 Stimulon vaccine adjuvant. Glaxo said an experimental melanoma treatment did not meet its first goal in a mid-stage clinical trial. Glaxo is studying an immune therapy that targets MAGE-A3, an antigen found in various cancers. The therapy includes Agenus’ SQ-21 Stimulon adjuvant, extracted from the bark of an evergreen called Soapbark.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week